Search Results

You are looking at 61 - 70 of 179 items for :

  • "acute myeloid leukemia" x
Clear All
Full access

Aung Naing, Lubomir Sokol and Alan F. List

. 22. Foran J Paquette R Copper M . A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed or are not eligible for conventional chemotherapy [abstract] . Blood 2002 ; 100

Full access

Constantine S. Mitsiades and Kenneth C. Anderson

-sensitive ovarian tumors . Nat Med 2003 ; 9 : 568 - 574 . 54. Melki JR Vincent PC Clark SJ . Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia . Cancer Res 1999 ; 59 : 3730 - 3740 . 55. Hegi ME Liu L Herman JG

Full access

Guru Subramanian Guru Murthy, Aniko Szabo, Laura Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Sameem Abedin and Ehab Atallah

Background Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) that is characterized by chromosomal translocation t(15;17) with fusion of PML-RARA genes and cell-cycle arrest at the promyelocyte stage. 1 APL

Full access

Sara E. Nunnery, Andrew E. Fintel, W. Clay Jackson, Jason C. Chandler, Michael O. Ugwueke and Mike G. Martin

urgent leukapheresis, a bone marrow biopsy was performed and a diagnosis of acute myeloid leukemia (AML) was made. He was started on induction chemotherapy with cytarabine, idarubicin, and cladribine (7+3+5). 4 The final bone marrow biopsy revealed high

Full access

Sophia Koo and Lindsey R. Baden

lymphoproliferative disorders . Blood 2002 ; 100 : 3121 – 3127 . 51. Ho AY Pagliuca A Kenyon M . Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia

Full access

Robert W. Carlson

neoplasms. Also in the congress, blood cancer experts described updates in treatment strategies for Hodgkin lymphoma, advances in first-line acute myeloid leukemia management, and progress in personalized therapeutic approaches in myelodysplastic syndromes

Full access

17 17 11.5 11.5 1437 1437 1440 1440 jnccn20195034 10.6004/jnccn.2019.5034 Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia Pollyea Daniel A. MD, MS 11 2019 17 17 11.5 11.5 1441 1441 1443 1443 jnccn20195031 10.6004/jnccn.2019

Full access

-Acquired Resistance in the Brain and Histologic Transformation in the Lung Expiration Date: 9/19/14 NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 2.2013 Expiration Date: 9/19/14 Controversies in the Treatment of Elderly Patients With Newly

Full access

Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies and Alexander J. Lazar

neoplasms. 13 – 34 We now have strong evidence to support molecular testing in patients with various types of cancer, including lung carcinoma, melanoma, colorectal carcinoma, and acute myeloid leukemia, as part of routine clinical practice and standard of

Full access

cancers and acute myeloid leukemia. The report grew out of the discussion held by the group in May 2011, when NCCN assembled the task force, comprising oncologists and pathologists from the NCCN Member Institutions and expert participants from the NCI and